Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

This publication has 49 references indexed in Scilit:

• Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization
  Archives of internal medicine (1960), 2004
• Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey
  American Journal of Kidney Diseases, 2003
• Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
  Kidney International, 2003
• Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
  New England Journal of Medicine, 2002
• Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
  New England Journal of Medicine, 2001
• Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
  New England Journal of Medicine, 2001
• Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
  Annals of Internal Medicine, 2001
• Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
  The Lancet, 1999
• The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease
  New England Journal of Medicine, 1994
• The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
  New England Journal of Medicine, 1993